Form 10-Q Journey Medical Corp For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
B.Riley Reiterates Buy Rating on Journey Medical Corp. (DERM)
August 13, 2024 6:55 AM EDTB.Riley analyst Kalpit Patel reiterated a Buy rating and $8.00 price target on Journey Medical Corp. (NASDAQ: DERM).
The analyst comments "Journey Medical (DERMBuy, $8 PT) reported 2Q earnings, with top-line revenues of $14.9M (vs. our $13.3M estimate), likely signaling stabilization in its dermatology-focused... More
